Bio-Techne Company (TECH) Jefferies London Healthcare Convention 2025 November 20, 2025 7:30 AM EST
Firm Contributors
James Hippel – Government VP of Finance & CFO
Convention Name Contributors
Tycho Peterson
Tycho Peterson
Presentation
Tycho Peterson
Okay. Nice. We will kick it off. I am Tycho Peterson from the Life Science crew. We’re happy to have Bio-Techne with us right now. Welcome.
Query-and-Reply Session
Tycho Peterson
Perhaps kick off with a bit only a fast look again on the fiscal first quarter, some offers and takes, however you probably did speak about form of core progress up 1%, perhaps setting apart the cell remedy form of noise right here. We’ll unpack that in a minute, however simply speak a bit bit about what you noticed within the quarter.
James Hippel
Government VP of Finance & CFO
Tycho, thanks for having us. Sure, the general progress for the quarter was adverse 1%, a bit bit — a end result that does not actually replicate our underlying efficiency since you already talked about we have been 1% constructive when you take 2 bigger firms that acquired their Quick Monitor designation and subsequently, did not order this 12 months in comparison with final 12 months, and that actually drove a adverse 200 foundation factors on the highest line.
However underlying, if you consider the top markets in addition to our 4 progress verticals, the top markets that did do some bit higher than we had anticipated was undoubtedly massive pharma, 30% of our revenues, and we proceed to be within the double digits efficiency there. And final 12 months, we — or final quarter, we have been really a bit nervous concerning the rhetoric with a number of the tariffs and most of the people have been pricing that we have been nervous that they’d faucet the brakes, however they did not. And that was a constructive for 1 / 4.
